MARKET

PIRS

PIRS

Pieris Pharmaceu
NASDAQ
0.3260
+0.0082
+2.58%
After Hours: 0.3280 +0.002 +0.61% 20:05 09/21 EDT
OPEN
0.3050
PREV CLOSE
0.3178
HIGH
0.3276
LOW
0.3025
VOLUME
859.54K
TURNOVER
0
52 WEEK HIGH
1.970
52 WEEK LOW
0.1616
MARKET CAP
32.23M
P/E (TTM)
-0.8780
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PIRS last week (0911-0915)?
Weekly Report · 3d ago
Weekly Report: what happened at PIRS last week (0904-0908)?
Weekly Report · 09/11 09:58
Weekly Report: what happened at PIRS last week (0828-0901)?
Weekly Report · 09/04 16:40
Pieris Pharmaceu: [Amend]Current report
Press release · 08/31 23:04
Weekly Report: what happened at PIRS last week (0821-0825)?
Weekly Report · 08/28 10:01
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 08/25 17:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 08/25 13:06
Why Affirm Holdings Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 08/25 12:27
More
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4Ra, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. Its IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.